Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
UCM301
ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study
- NCT04620239 ↗
- Active, not recruiting
- Steba Biotech S.A.
- Deep
We haven't built an HCP commentary report on UCM301 (padeliporfin VTP in Transitional Cell Cancer of Renal Pelvis and Ureter) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on UCM301 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 16 | |
| YouTube | 5 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- Multicenter Phase 3 Pivotal Study to Evaluate the Safety and Efficacy of TOOKAD (Padeliporfin) Vascular Targeted Photodynamic Therapy in the Treatment of Low Grade Upper Tract Urothelial Cancer
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Transitional Cell Cancer of Renal Pelvis and Ureter
- Interventions
- padeliporfin VTP
- Arms
- padeliporfin VTP · Experimental
- Enrollment
- 89
- Primary outcomes
- Number of patients with absence of UTUC tumors in the entire ipsilateral calyces, renal pelvis and ureter
- Sponsor
- Steba Biotech S.A. with PrimeVigilance, ICON plc
- Start
- Mar 22, 2021
- Primary completion
- Jul 1, 2026
- Results posted
- No
- Registry record
- NCT04620239 · updated Jul 30, 2026